Capacity boost and cold-chain focus, Catalent’s Bloomington site highlights Drug Product services

Catalent’s Drug Product services at its Bloomington, Indiana site target late-stage and commercial injectable biologics with expanded filling lines and packaging. The CDMO leans on high-speed syringes, vials and cartridges plus cold-chain logistics for biotech clients.

Edited by ad hoc news New Releases & Launches Desk. Reviewed before publication on 06/16/2026 at 11:25 AM ET. Details in the imprint.

Catalent’s Drug Product services centered at its Bloomington, Indiana facility are drawing renewed attention from biotech clients as the company emphasizes expanded capacity for late-stage and commercial injectable biologics. The campus combines high-speed vial, syringe and cartridge filling with integrated visual inspection, packaging and cold-chain logistics aimed at complex parenteral therapies. For drug developers looking to move from clinical to commercial scale, the site is positioned as one of Catalent’s key hubs for biologics drug product manufacturing in North America.

What Catalent’s Drug Product services at Bloomington cover

The Bloomington site, acquired in 2017 and expanded since, offers sterile drug product manufacturing for biologics and sterile injectables, including large-scale filling of vials, prefilled syringes and cartridges for autoinjectors and other injection devices. According to Catalent’s own descriptions, the campus provides multiple high-speed filling lines, lyophilization capacity and automated inspection and packaging operations designed to support both clinical and commercial supply of biologic medicines. Catalent’s official Drug Product capability page outlines these services as a core pillar of its biologics offering.

A central focus of the Bloomington operations is flexibility in handling different dosage forms and container types, allowing customers to choose between traditional glass vials, ready-to-use prefilled syringes and cartridges that can be integrated into pen or autoinjector systems. This flexibility is important for biologic drugs that may start in vials during early development and later shift to patient-friendly delivery formats for chronic therapies. The facility’s support for both lyophilized and liquid formulations, combined with process development and analytical services, is intended to help sponsors optimize stability and manufacturability as molecules progress through the clinic.

Catalent also highlights its cold-chain management and controlled-temperature storage capabilities at Bloomington, a critical requirement for many modern biologics and advanced therapies that are temperature-sensitive throughout manufacturing, packaging, warehousing and distribution. The site’s infrastructure is built to maintain strict temperature control from filling through release and shipment, including refrigerated and frozen storage conditions, which is increasingly important for monoclonal antibodies and other large-molecule therapeutics. For clients, this reduces the need to coordinate multiple vendors and helps centralize responsibility for maintaining product quality across the supply chain.

Drug Product services at Bloomington sit within Catalent’s broader biologics network, which includes additional facilities in Brussels, Anagni and other global locations. The company’s strategy has been to create a network that can support global launches and regional supply by pairing drug substance capabilities with drug product fill-finish and packaging. Industry coverage notes that Catalent’s biologics businesses, including drug product and related services, have been a significant contributor to its revenue growth over recent years as more biologic and injectable therapies enter the market. Analysts often cite the Bloomington facility as one of the company’s flagship biologics assets when discussing capacity, quality track record and its role in major vaccine and biologic programs. A detailed overview of this network was reported in a recent FiercePharma analysis of biologics fill-finish demand, which referenced Catalent among key contract manufacturers in the segment.

For drug developers, one recurring theme is the demand for scalable fill-finish partners that can handle both high-volume commercial launches and smaller, specialized biologic products without compromising quality or timelines. Catalent positions its Drug Product services, and Bloomington in particular, as suited to this mix, emphasizing regulatory experience with agencies including the FDA and EMA, a history of commercial product approvals and support for technology transfers. The site’s experience with complex projects, such as large-scale vaccine programs, has been cited by industry observers as evidence that it can manage the operational challenges associated with ramping production quickly while maintaining compliance and quality standards. A recent overview by Reuters on global contract development and manufacturing organizations noted that biologics and sterile injectables are among the fastest-growing outsourcing segments for players like Catalent. That context was highlighted in a Reuters report on Catalent’s strategic review and M&A interest, which underscored the value of its biologics drug product sites.

Within Catalent’s overall portfolio, the Drug Product business and facilities such as Bloomington are strategically important because they sit at the point where clinical innovation meets commercial supply, often generating recurring revenue over the lifecycle of a therapy. As more large-molecule drugs, including monoclonal antibodies and next-generation biologics, seek contract partners for fill-finish, these capabilities are likely to remain a focus for the company’s capital allocation and operational updates. Shares of Catalent (ISIN US1488061029) traded on the New York Stock Exchange at around $56 in recent sessions, with investors closely watching how its biologics and drug product capacities contribute to long-term growth alongside any strategic transactions.

Catalent Drug Product services in brief

• Product: Drug Product services (Bloomington, Indiana)
• Manufacturer: Catalent, Inc.
• Category: New Release/Launch - biologics drug product services
• Launch date: Expanded operations built on the former Cook Pharmica site acquired in 2017, with ongoing capacity additions
• MSRP / Price: Service-based pricing, typically under confidential contract terms
• Availability: Offered globally to biopharma clients, with manufacturing at Bloomington, Indiana and integration into Catalent’s biologics network
• Target audience: Biotech and pharmaceutical companies developing and commercializing sterile injectable biologics
• Key differentiator / USP: High-speed vial, syringe and cartridge filling combined with cold-chain logistics and integrated inspection and packaging for late-stage and commercial biologics

This article was a.i.-assisted and editorially reviewed. Product information without warranty; prices and availability may change at short notice. Not investment advice and not a buy or sell recommendation. Trading involves risk up to and including the total loss of invested capital.